Volume | 738,059 |
|
|||||
News | - | ||||||
Day High | 66.12 | Low High |
|||||
Day Low | 64.50 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Cytokinetics Inc | CYTK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
65.00 | 64.50 | 66.12 | 65.34 | 64.80 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
11,677 | 738,059 | US$ 65.42 | US$ 48,286,731 | - | 25.98 - 110.25 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:56:40 | 1 | US$ 63.60 | USD |
Cytokinetics (CYTK) Options Flow Summary
Cytokinetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.73B | 103.00M | - | 7.53M | -526.24M | -5.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cytokinetics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYTK Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 66.88 | 68.76 | 64.10 | 66.28 | 1,193,866 | -3.27 | -4.89% |
1 Month | 69.88 | 75.71 | 64.10 | 69.67 | 1,056,313 | -6.27 | -8.97% |
3 Months | 80.49 | 84.05 | 61.33 | 70.35 | 2,032,116 | -16.88 | -20.97% |
6 Months | 33.03 | 110.25 | 30.37 | 70.41 | 2,817,459 | 30.58 | 92.58% |
1 Year | 37.94 | 110.25 | 25.98 | 61.14 | 1,893,754 | 25.67 | 67.66% |
3 Years | 26.70 | 110.25 | 17.72 | 48.02 | 1,400,244 | 36.91 | 138.24% |
5 Years | 9.19 | 110.25 | 7.01 | 38.78 | 1,191,218 | 54.42 | 592.17% |
Cytokinetics Description
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. |